Cubist Pharmaceuticals (CBST)
Cubist Pharmaceuticals Cash and ST Investments: 790.16M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CBST Cash and ST Investments Rankings
| Overall | 86th percentile | 608 of 4365 |
| Sector | 91st percentile | 44 of 504 in Healthcare |
| Industry | 89th percentile | 4 of 39 in Drug Manufacturers - Other |
CBST Cash and ST Investments Range, Past 5 Years
| Minimum | 299.52M | Mar 2008 |
| Maximum | 1.011B | Jun 2011 |
| Average | 548.00M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these CBST related companies
CBST News
Cubist Pharmaceuticals Marks 20th Anniversary by Making Its Largest-Ever Commitment to STEM Programs
May 16, 9:00AM Business Wire
May 16, 9:00AM Business Wire
Stocks watchlist for Monday.$IPHS,$CLDX,$CBST,$ECHO,$NEOG,$ACFN,$MNTX,$XNPT.That is all for now. Will try to do more research tonight
about 15 days ago by traderNC
about 15 days ago by traderNC
$CBST forms bullish "Continuation Diamond" chart pattern. http://stks.co/3dhO
about 25 days ago by RecogniaEvents
about 25 days ago by RecogniaEvents
$CBST filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3X0c
about 32 days ago by MarketBrief
about 32 days ago by MarketBrief
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest ROE
Apr 24, 3:44AM Benzinga
Apr 24, 3:44AM Benzinga
Needham & Company maintains a 'Hold' on Cubist Pharmaceuticals (CBST); Cubicin Sales Beat; Awaiting Progression
Apr 19, 7:36AM Street Insider
Apr 19, 7:36AM Street Insider
Rockwell Collins, Inc. (COL) Reports In-Line Q1 EPS; Guides Lower for FY12 Revs
Apr 19, 7:30AM Street Insider
Apr 19, 7:30AM Street Insider
Cubist Pharma (CBST) Reports Results from ENTEREG Phase 4 Study in Radical Cystectomy Patients
Apr 17, 5:17PM Street Insider
Apr 17, 5:17PM Street Insider
Cubist Announces Positive Results from ENTEREG® Phase 4 Study in Patients Undergoing Radical Cystectomy
Apr 17, 5:00PM Business Wire
Apr 17, 5:00PM Business Wire
$CBST cont.'s Bearish here since falling out of Bearish Wedge. Cont. to Short.
about 41 days ago by Fibline
about 41 days ago by Fibline
Oppenheimer Raises PT and Estimates on Cubist Pharmaceuticals (CBST); Guidance Likely Conservative
Apr 04, 11:05AM Street Insider
Apr 04, 11:05AM Street Insider
Brean Murray Carret & Co. Starts Cubist Pharmaceuticals (CBST) at Hold; Waiting Until Next Growth Driver
Apr 04, 7:58AM Street Insider
Apr 04, 7:58AM Street Insider
Cubist Pharmaceuticals to Announce Q112 Financial Results on Wednesday, April 18th, 2012
Apr 02, 10:44AM Business Wire
Apr 02, 10:44AM Business Wire
Cubist Pharma - Ascending Triangle - Riding 50 EMA on Dips - 15.85% Short Float $CBST http://chart.ly/ug77keo
about 95 days ago by OptionsHawk
about 95 days ago by OptionsHawk
$CBST to Present at February/March Investor Conferences on Feb 28th and Mar 5. http://stks.co/2TmH
about 98 days ago by abubnic
about 98 days ago by abubnic
$CBST http://stks.co/2TRX looking to raise the roof over 42.40, nice long rising trend support
about 99 days ago by harmongreg
about 99 days ago by harmongreg
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CBST | 39.87 | -0.04 | -0.10% | 2.510B |
| CBSH | 39.00 | -0.06 | -0.15% | 3.473B |
| CBS | 31.56 | -0.07 | -0.22% | 20.48B |
| CBRX | 0.6602 | +0.02 | +3.27% | 57.66M |
| CBRL | 59.82 | +0.35 | +0.59% | 1.375B |
| CBPO | 7.90 | -0.03 | -0.38% | 202.24M |
| CBP | 0.56 | +0.01 | +1.82% | 20.85M |
| CBOU | 11.61 | +0.25 | +2.20% | 243.23M |
| CBOE | 25.24 | -0.15 | -0.59% | 2.241B |
| CBNJ | 8.19 | -0.03 | -0.36% | 109.01M |
